The proposal that reduced levels of FBN1 EGFD hydroxylation can cause Traboulsi and Marfan syndrome–associated connective tissue defects raises the question of whether reported small-molecule inhibitors of AspH (65, 76, 77, 125, 126, 127, 128, 129) could trigger similar connective tissue defects, a possibility that deserves attention because increased AspH levels on the surface of cancer cells have been correlated with worse clinical prognosis, rendering AspH a potential target for cancer treatment (130, 131, 132, 133). The gene discussed is FBN1; the disease is Marfan syndrome.